<DOC>
	<DOCNO>NCT00621582</DOCNO>
	<brief_summary>The objective present Post Marketing Surveillance Study ( PMS ) study evaluate safety effectiveness tiotropium bromide ( Spiriva® ) 18 µg daily 5,000 patient COPD vary severity 8 week .</brief_summary>
	<brief_title>Spiriva® 18µg Once Daily Chinese COPD Patients Different Disease Severities</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Incl . Criteria Patients clinical diagnosis stable Chronic Obstructive Pulmonary Disease ( COPD ) accord definition China COPD guideline . Patients 40 year old Patient history hypersensitivity tiotropium bromide , atropine and/or derivant , i.e . ipratropium , component Spiriva® Patient know narrowangle glaucoma Patient know symptomatic prostatic hyperplasia and/or bladderneck obstruction Patient know moderate severe renal impairment ( i.e. , creatinin clearance &lt; =50ml/min ) Pregnant nurse woman Patient significant disease COPD would exclude him/her participate study Patients condition list [ special precaution ] , [ drug interaction ] , [ contraindication ] Spiriva® China package insert Patients sign informed consent study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>